Start the conversation
In the late 1980s, while working as a banking analyst, I actually got up close and personal with Carl Reichardt, who was CEO of Wells Fargo & Co. (NYSE: WFC) at the time.
And something he shared with me in his spacious San Francisco office has stayed with me ever since.
I asked Reichardt if Wells Fargo's focus on home and middle-market loans might be considered boring when other banks were chasing more exotic investments with higher yields.
He looked me straight in the eyes and said, "If plain vanilla means making a lot of money, then color me plain vanilla."
I bring this up because I've spotted a dental-technology firm that investors might at first consider ho-hum - but that's soared 80% in the past year. That's five times the gains of the S&P 500 during the same period.
Yes, investing in a dental company may sound dull - or maybe even painful - but this is actually a profit-producing tech superstar.
A Shopping List – and a Recipe
I've been thinking a lot about dental tech lately because I have an appointment to get an implant. It's an expensive procedure, one that will cost me at least $7,500, not counting insurance reimbursement.
So, I know from firsthand experience that patients are willing to pay a bunch of money to fix their teeth.
A lot of patients.
Indeed, the firm I've spotted - whose technology keeps people's teeth in proper alignment - has a potential client base of 10 million teenagers and young adults.
Align Technology Inc. (Nasdaq: ALGN) only counts about half of that target market as patients fit for its platform. But because it has so far hit only about 7% of its audience, the Silicon Valley firm still has a target-rich opportunity in front of it - and a long way to grow.
No wonder Align set the market on fire April 28, when its stock price soared more than 13% on six times its normal volume.
That's a very bullish sign.
At the time, Align's first-quarter sales hit a record. Overall they grew by 30%. Even better, offshore sales jumped by 41%, meaning this is a medtech leader with the potential to go truly global - and reach billions more customers.
With that in mind, let's put Align through Your Tech Wealth Blueprint - our five rules for spotting - and creating - tech wealth. These five guidelines are kind of like a shopping list, or even a recipe - a shopping list that helps you find great companies... and a recipe for the kind of wealth that gives you a stress-free life today and a worry-free retirement tomorrow
Take a look...
Rule No. 1: Great Companies Have Great Operations
We're always on the lookout for well-run firms with top-notch leaders.
You'd be hard pressed find a sav…
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.